Comprehensive Cancer Panel PLUS

Multi-biomaker NGS assay for solid tumors that evaluates >500 genes for SNVs, Indels, CNVs, LOH, Gene Fusions and also includes TMB and MSI. (FFPE samples)

Comprehensive Cancer Panel

Multi-biomaker NGS assay that covers 161 of the most clinically relevant cancer genes in solid tumors (FFPE samples)

Microsatellite Instability (MSI) Analysis

We evaluate 5 markers in samples containing mismatch repair defects in solid tumors (FFPE affected + non-affected tissue samples)

Colorectal Cancer (Lynch + FAP)

Includes 19 relevant genes for colorectal cancer assessment including MMR (mismatch repair pathway) genes: MLH1, MSH2, MSH6 and PMS2

BRCA Test

Somatic and germline patogenic variants for BRCA1 and BRCA2 genes (FFPE + blood)

BRCA Expanded Test

Analysis of 21 cancer genes including homologus repair pathway and MMR in FFPE biopsies
(Germline testing also available)

Clarity Test

Analysis of 39 genes relevant in Hereditary Cancer Syndromes (germline mutations)

Pan-Cancer Liquid Biopsy

Using 1 single blood sample we evaluate 52 clinically relevant genes from cell-free DNA (cfDNA) and cell-free RNA (cfRNA) found in the plasma fraction of whole blood.

Colorectal Cancer Liquid Biopsy

Using 1 single blood sample we assay 14 clinically relevant genes in colorectal cancer from cell-free DNA (cfDNA) found in the plasma fraction of whole blood.

Breast Cancer Liquid Biopsy

Using 1 single blood sample we test 12 clinically relevant genes in breast cancer from cell-free DNA (cfDNA) found in the plasma fraction of whole blood.

Lung cancer liquid biopsy

Using 1 single blood sample this test evaluates 12 clinically relevant genes in lung cancer from cell-free DNA (cfDNA) and cell-free RNA (cfRNA) found in the plasma fraction of whole blood.